The company's latest presentation supports the idea that its lead program will make billions.

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from clinical trials of its weight loss drugs.

Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations. Patients who received the higher dose 100 milligram version of the oral drug,

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space. Viking reported positive results for its new obesity pill,

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage biopharma announced Monday. In a study that tested the highest dosage of 100-mg, the drug — known as KV2735 — resulted in an average of 6.8% body weight reduction after 28 days compared to placebo.

For high-profile biotech Viking Therapeutics (NASDAQ: VKTX), Monday was very much a good news/bad news kind of day. The company reported quite encouraging clinical results from a version of its investigational weight-loss drug. Before long, however, this was overshadowed by promising news from rival developers of similar treatments.

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories of the American company Viking Therapeutics, which has achieved a

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.